23andMe Announces Extension of GSK Collaboration and Update on Joint Immuno-oncology Program
January 18, 2022 06:55 ET
|
23andMe Holding Co.
GSK extends exclusive target discovery period of collaboration for a fifth year to discover and validate novel drug targets using 23andMe’s proprietary genetic and health survey database 23andMe...
23andMe Receives FDA Clearance for Direct-to-Consumer Genetic Test on a Hereditary Prostate Cancer Marker
January 10, 2022 08:00 ET
|
23andMe Holding Co.
SUNNYVALE, Calif., Jan. 10, 2022 (GLOBE NEWSWIRE) -- 23andMe Holding Co. (Nasdaq: ME) (“23andMe”), a leading consumer genetics and research company, today received FDA clearance for a genetic health...
23andMe Initiates Phase 1 Clinical Trial for First Wholly-Owned Immuno-oncology Antibody for Patients with Solid Tumors
January 06, 2022 09:00 ET
|
23andMe Holding Co.
23ME-00610 targets CD200R1, an important regulator of T cells and myeloid cells CD200R1 was identified as a promising immuno-oncology target through 23andMe’s proprietary genetic and health survey...
23andMe Announces the Results of the Completed Redemption of All Outstanding Warrants
December 28, 2021 16:05 ET
|
23andMe Holding Co.
SUNNYVALE, Calif., Dec. 28, 2021 (GLOBE NEWSWIRE) -- 23andMe Holding Co. (Nasdaq: ME) (“23andMe”), a leading consumer genetics and research company, today announced the results of the completed...
23andMe Announces the Appointment of Joseph R. Arron, M.D., Ph.D. as Chief Scientific Officer
November 30, 2021 09:15 ET
|
23andMe Holding Co.
SUNNYVALE, Calif., Nov. 30, 2021 (GLOBE NEWSWIRE) -- 23andMe Holding Co. (Nasdaq: ME) (“23andMe”), a leading consumer genetics and therapeutics company, today announced the appointment of Joseph R....
23andMe Announces Redemption of All Outstanding Warrants
November 22, 2021 16:15 ET
|
23andMe Holding Co.
SUNNYVALE, Calif., Nov. 22, 2021 (GLOBE NEWSWIRE) -- 23andMe Holding Co. (Nasdaq: ME) (“23andMe”), a leading consumer genetics and research company, today announced that it will redeem all of its...
23andMe Reports FY2022 Second Quarter Financial Results
November 10, 2021 16:05 ET
|
23andMe Holding Co.
Second quarter revenue of $55 millionRecent addition of telemedicine platform further advances vision of individualized primary care that empowers consumers to live healthier lives SUNNYVALE,...
23andMe Provides Updated Timing for FY2022 Second Quarter Financial Results and Announces New Online Q&A Platform for Shareholders
November 03, 2021 16:30 ET
|
23andMe, Inc.
SUNNYVALE, Calif., Nov. 03, 2021 (GLOBE NEWSWIRE) -- 23andMe Holding Co. (Nasdaq: ME) (“23andMe”), a leading consumer genetics and research company, announced today that it will report financial...
23andMe Announces the Closing of its Acquisition of Lemonaid Health
November 01, 2021 16:05 ET
|
23andMe, Inc.
SUNNYVALE, Calif., Nov. 01, 2021 (GLOBE NEWSWIRE) -- 23andMe Holding Co. (Nasdaq: ME) (“23andMe”), a leading consumer genetics and research company, today announced that it has completed its...
23andMe Agrees to Acquire Lemonaid Health
October 22, 2021 06:55 ET
|
23andMe, Inc.
Acquisition provides telemedicine platform for 23andMe to advance its vision of individualized primary care that empowers consumers to live healthier lives 23andMe to host investor webcast today at...